Opinion

Video

Current Front-Line Targeted Treatments in Ph+ ALL

Elias Jabbour, MD, provides an overview of the history of targeted agents and the use of tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Related Videos
Frederick L. Locke, MD
2 experts in this video
2 experts in this video
Dr Rebecca Haberman
1 expert is featured in this series.
Dr Rebecca Haberman
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo